Encepur is a vaccine that consists of an inactivated and purified Tick-Borne Encephalitis (TBE) virus/strain.
Encepur is indicated for active immunization of high-risk populations against tick-borne encephalitis (TBE).
Encepur is administered as an intramuscular injection. It has unique dosing flexibility supported by proven efficacy and long-term persistence data.
October 21, 2019: Bavarian Nordic announced that it has entered an agreement with GlaxoSmithKline to acquire the manufacturing and global rights to Rabipur®/RabAvert® and Encepur®, two commercial vaccines with combined annual sales of approximately EUR 175 million holding strong positions in growing markets. Rabipur/RabAvert provides pre- and post-exposure protection against rabies, while Encepur protects against European (Western) tick-borne encephalitis (TBE) virus.
Clinical Trial NCT03294135: The Aim of This Study is to Investigate the Persistence of Antibody Response in Adults up to 15 Years After One Booster Dose of GlaxoSmithKline (GSK) Biologicals' Encepur Adults Vaccine
- The purpose of this study is to continue the evaluation of antibody persistence through 11 to 15 years after the first booster with the Tick-Borne Encephalitis (TBE) vaccine.
- This study will further investigate the booster response in subjects who will receive their second booster dose* in this study.
* Any booster given in this study will be the second that the subject has received (with regard to the follow-up of the previous study).